Novartis Faces Board Shake-up Calls After Trial Failures
Shareholder Artisan Partners urges Novartis to overhaul its board and strategy following two major clinical trial setbacks.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
3 publishers have covered this in 8 articles since 8 Sept 2026. STAT published first, on 8 September at 07:28 UTC; The New York Times followed 6h 07m later. The most recent article, from STAT, appeared on 11 September at 13:56 UTC.
Outlets reporting it: The New York Times (major outlet), Bloomberg Markets (major outlet), STAT.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- STATSTAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company
- STATSTAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
- The New York TimesThe Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
- STATSTAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea
- Bloomberg MarketsNovartis Needs Board Shakeup and M&A Revamp, Investor Says
- STATSTAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
- STATSTAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
- STATSTAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Novartis Needs Board Shakeup and M&A Revamp, Investor Says Bloomberg Markets ·
- The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists The New York Times ·
- STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more STAT
- STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field STAT
- STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more STAT
- STAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea STAT
- STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more STAT
- STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company STAT
In this story
- Novartis
- Artisan Partners